• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

24
2
1
1
1

COUNTRY

1

CATEGORIES

  • 11
  • 7
  • 5
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

13
15
18
35

PUBLISHED

0
2
3
35

PRODUCT TYPE

24
11

Search "Wyeth: Performance, Products, Pipeline and Potential" returned 35 results.

PRODUCT TITLE
Wyeth: PharmaVitae Profile Wyeth: PharmaVitae Profile - Product Thumbnail Image

Wyeth: PharmaVitae Profile

This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and...

March 2009
FROM
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines - Product Thumbnail Image

Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines

Introduction Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeths...

December 2008
FROM
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights - Product Thumbnail Image

The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights

Pain continues to present numerous challenges to the biopharmaceutical industry According to the American Academy of Pain Medicine, over 76 million Americans suffer from pain Indeed, pain affects more...

October 2010
FROM
Infectious Diseases Vaccine Market Overview Infectious Diseases Vaccine Market Overview - Product Thumbnail Image

Infectious Diseases Vaccine Market Overview

Introduction Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth’s...

October 2010
FROM
The CNS Market Outlook to 2010 The CNS Market Outlook to 2010 - Product Thumbnail Image

The CNS Market Outlook to 2010

Maximize future market opportunity with the help of this NEW report... The traditional markets of depression and schizophrenia will see further product launches in the next few years, however many...

October 2005
FROM
IMS Company Profiles:Wyeth IMS Company Profiles:Wyeth - Product Thumbnail Image

IMS Company Profiles:Wyeth

This Company Profile gives you the authoritative insight into a company at a strategic and local level Each individual profile analyzes the critical components that make up a pharmaceutical company,...

February 2009

Noven Pharmaceuticals, Inc. - Strategic SWOT Analysis Review

Noven Pharmaceuticals, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a...

February 2014
FROM
Genzyme Corporation: PharmaVitae Profile Genzyme Corporation: PharmaVitae Profile - Product Thumbnail Image

Genzyme Corporation: PharmaVitae Profile

Introduction This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline...

August 2010
FROM

ImmunoGen, Inc. (IMGN) - Financial and Strategic SWOT Analysis Review

ImmunoGen, Inc. (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData...

January 2014
FROM
Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review

Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review Summary Immtech Pharmaceuticals, Inc. (Immtech) is a pharmaceutical company that focuses on the global opportunities...

September 2012
FROM
Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI - Product Thumbnail Image

Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years They enable companies to focus on core competencies such as drug discovery...

March 2009
FROM

Companion Biomarkers in Drug Development

Companion biomarkers are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic This linkage can be an important component of the drug development...

August 2013
FROM

Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Summary Our pharmaceuticals report, “Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022” provides Torisel sales forecasts...

March 2012
FROM
Commercial And Pipeline Insight: HRT For Menopausal Symptoms – A New Class Restores An Old Market Commercial And Pipeline Insight: HRT For Menopausal Symptoms – A New Class Restores An Old Market - Product Thumbnail Image

Commercial And Pipeline Insight: HRT For Menopausal Symptoms – A New Class Restores An Old Market

Introduction In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT...

April 2008
FROM

Anti-Infective Drugs Markets

Six infectious diseases -- pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS -- account for half of all premature deaths worldwide, killing mostly children and young adults,...

October 2010
FROM
Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review

Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review Summary Crucell N.V. (Crucell) is a biopharmaceutical company engaged in developing, producing and marketing products for the treatment...

September 2011
FROM
US Cancer Pain Report US Cancer Pain Report - Product Thumbnail Image

US Cancer Pain Report

The US market for the drug treatment of cancer pain in 2008 is valued at $3 1 billion, according to US Cancer Pain Report The cancer pain market is dominated by opioid drugs, a trend expected to continue...

February 2009
FROM
Bionovo, Inc. (BNVI) - Financial and Strategic SWOT Analysis Review Bionovo, Inc. (BNVI) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Bionovo, Inc. (BNVI) - Financial and Strategic SWOT Analysis Review

Bionovo, Inc. (BNVI) - Financial and Strategic SWOT Analysis Review Summary Bionovo, Inc. (Bionovo) is a biopharmaceutical company that mainly focuses on the discovery and development of safe and...

September 2011
FROM
Amgen: Profile, Patents and Pipeline Amgen: Profile, Patents and Pipeline - Product Thumbnail Image

Amgen: Profile, Patents and Pipeline

Amgen is the world's largest biotechnology company and the eighth largest pharmaceutical company worldwide. Revenues have nearly doubled in the last three years, going from $5.52 billion in 2002 to...

September 2005
FROM
Strategic Analysis of World Psychiatric Therapeutics Markets Strategic Analysis of World Psychiatric Therapeutics Markets - Product Thumbnail Image

Strategic Analysis of World Psychiatric Therapeutics Markets

Loss of Patent Protection Challenges Market Growth The imminent patent expiration for key anticonvulsants such as Neurontin (in 2004), Topamax (in 2004), and Trileptal (in 2005) is expected to create...

September 2004
FROM
Loading Indicator